vs
Side-by-side financial comparison of GERON CORP (GERN) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $47.2M, roughly 1.2× GERON CORP). GERON CORP runs the higher net margin — -39.0% vs -83.0%, a 44.0% gap on every dollar of revenue. On growth, GERON CORP posted the faster year-over-year revenue change (67.1% vs 36.9%). Over the past eight quarters, GERON CORP's revenue compounded faster (1597.0% CAGR vs 48.5%).
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
GERN vs RYTM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $57.3M |
| Net Profit | $-18.4M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -29.4% | -82.2% |
| Net Margin | -39.0% | -83.0% |
| Revenue YoY | 67.1% | 36.9% |
| Net Profit YoY | 30.3% | -9.6% |
| EPS (diluted) | $-0.03 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.3M | ||
| Q3 25 | $47.2M | $51.3M | ||
| Q2 25 | $49.0M | $48.5M | ||
| Q1 25 | $39.6M | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | $28.3M | $33.3M | ||
| Q2 24 | $882.0K | $29.1M | ||
| Q1 24 | $304.0K | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-18.4M | $-52.9M | ||
| Q2 25 | $-16.4M | $-46.6M | ||
| Q1 25 | $-19.8M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-26.4M | $-43.6M | ||
| Q2 24 | $-67.4M | $-32.3M | ||
| Q1 24 | $-55.4M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | -29.4% | -102.6% | ||
| Q2 25 | -25.4% | -93.4% | ||
| Q1 25 | -42.2% | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | -99.8% | -132.0% | ||
| Q2 24 | -7860.9% | -139.2% | ||
| Q1 24 | -18465.1% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | -39.0% | -103.1% | ||
| Q2 25 | -33.4% | -96.1% | ||
| Q1 25 | -50.1% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -93.5% | -131.2% | ||
| Q2 24 | -7639.8% | -110.9% | ||
| Q1 24 | -18220.4% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | $-0.03 | $-0.82 | ||
| Q2 25 | $-0.02 | $-0.75 | ||
| Q1 25 | $-0.03 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $-0.04 | $-0.73 | ||
| Q2 24 | $-0.10 | $-0.55 | ||
| Q1 24 | $-0.09 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.1M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $248.7M | $139.1M |
| Total Assets | $567.4M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $388.9M | ||
| Q3 25 | $78.1M | $416.1M | ||
| Q2 25 | $77.7M | $291.0M | ||
| Q1 25 | $83.7M | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | $60.3M | $298.4M | ||
| Q2 24 | $116.9M | $319.1M | ||
| Q1 24 | $189.8M | $201.2M |
| Q4 25 | — | $139.1M | ||
| Q3 25 | $248.7M | $148.8M | ||
| Q2 25 | $259.5M | $-11.9M | ||
| Q1 25 | $268.2M | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | $292.3M | $11.2M | ||
| Q2 24 | $306.7M | $39.3M | ||
| Q1 24 | $344.9M | $61.6M |
| Q4 25 | — | $480.2M | ||
| Q3 25 | $567.4M | $506.9M | ||
| Q2 25 | $555.2M | $372.7M | ||
| Q1 25 | $562.5M | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | $444.9M | $363.6M | ||
| Q2 24 | $449.4M | $381.8M | ||
| Q1 24 | $482.1M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.6M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-25.4M | ||
| Q3 25 | $-13.6M | $-26.6M | ||
| Q2 25 | $-27.4M | $-23.3M | ||
| Q1 25 | $-48.0M | $-40.4M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $-58.9M | $-25.2M | ||
| Q2 24 | $-53.5M | $-29.1M | ||
| Q1 24 | $-62.3M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-53.7M | — | ||
| Q1 24 | $-62.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6086.6% | — | ||
| Q1 24 | -20680.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 23.4% | — | ||
| Q1 24 | 202.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
